4//SEC Filing
Nabriva Therapeutics AG 4
Accession 0001104659-17-033537
CIK 0001641640operating
Filed
May 16, 8:00 PM ET
Accepted
May 17, 7:01 PM ET
Size
20.2 KB
Accession
0001104659-17-033537
Insider Transaction Report
Form 4
Talbot George Harrison
Director
Transactions
- Exercise/Conversion
Common Shares
2017-02-16+502→ 3,351 total - Exercise/Conversion
Common Shares
2017-02-16+578→ 4,084 total - Exercise/Conversion
Common Shares
2017-02-16+155→ 3,506 total - Sale
Common Shares
2017-05-15$101.50/sh−50$5,075→ 4,034 total - Sale
Common Shares
2017-05-16$102.27/sh−50$5,113→ 3,984 total - Sale
Common Shares
2017-05-16$103.00/sh−100$10,300→ 3,884 total - Exercise/Conversion
Stock Option
2017-02-16−502→ 0 totalExp: 2017-09-27→ Common Shares (502 underlying) - Exercise/Conversion
Stock Option
2017-02-16−155→ 0 totalExp: 2017-09-27→ Common Shares (155 underlying) - Exercise/Conversion
Stock Option
2017-02-16−578→ 135 totalExp: 2017-09-27→ Common Shares (578 underlying)
Footnotes (9)
- [F1]This transaction is being reported late due to an administrative oversight.
- [F2]The exercise price was Euro 6.72 per common share.
- [F3]The common shares whose sale is reported on this line are represented by American Depositary Shares ("ADSs"). Each ADS represents one tenth (1/10) of a common share of Nabriva Therapeutics AG. The reporting person may hold both common shares and ADSs representing common shares, and Column 5 reports such holdings on an aggregate basis in terms of the corresponding number of common shares.
- [F4]The price of $101.50 per common share was derived from the sale price on May 15, 2017, of $10.15 per ADS, multiplied by ten.
- [F5]The price of $102.268 per common share was derived from the sale price on May 16, 2017, of $10.2268 per ADS, multiplied by ten.
- [F6]The price of $103.00 per common share was derived from the sale price on May 16, 2017, of $10.30 per ADS, multiplied by ten.
- [F7]This option was granted on June 12, 2009 and is fully vested.
- [F8]This option was granted on January 29, 2010 and is fully vested.
- [F9]This option was granted on August 31, 2014. Vesting began on August 31, 2014 and ends on September 30, 2017. Twenty-five percent (25%) of the option vested on December 31, 2014, a further twenty-five percent (25%) of the options vested on December 31, 2015, and the remaining fifty percent (50%) vests on a monthly pro-rata basis over the remaining vesting period.
Documents
Issuer
Nabriva Therapeutics AG
CIK 0001641640
Entity typeoperating
IncorporatedIreland
Related Parties
1- filerCIK 0001641640
Filing Metadata
- Form type
- 4
- Filed
- May 16, 8:00 PM ET
- Accepted
- May 17, 7:01 PM ET
- Size
- 20.2 KB